US Axial Spondyloarthritis Market outlook to 2028

Market Overview:

The United States Axial Spondyloarthritis market is primarily concerned with the diagnosis and treatment of Axial Spondyloarthritis. It is an autoimmune condition which is associated with causing pain and inflammation in the spine. There are two types of Axial Spondyloarthritis, i.e., Ankylosing Spondylitis and Non-radiographic Spondyloarthritis.

According to Ken Research, this market is anticipated to grow at a CAGR of 9.5% in between 2022-2028 owing to rise in cases of AxSpA, advanced diagnostics techniques, growing methods of treating AxSpA, and rising cases of chronic diseases.

Ankylosing Spondylitis and Non-radiographic Axial Spondyloarthritis are the two types of Axial Spondyloarthritis (AxSpA) which belong to the family of autoimmune diseases. The prevalence of AxSpA has been constantly rising in the United States. As of now, its prevalence is about 0.9% to 1.4% which is about 1.7 million to 2.7 million people. With this high prevalence, the need not only correctly diagnose but also to treat the AxSpA also rises which is the major factor responsible for the growth of US AxSpA market. Technology is constantly evolving and technology is playing a major role in the diagnosis of AxSpA. Various technologies such as MRI, CT scans, Ultrasound, various blood tests, gene testing etc. are used. These technologies help in pumping the US AxSpA market. Moreover, there also have been many treatment methods such as NSAIDs, Sulfasalazine, Analgesics, Biologics etc. The availability of many treatment methods also accelerate this market. Furthermore, the rising heath expenditure in the US also accelerates this market. In 2021, government invested ~$4 Tn in the healthcare sector. Which also helps in the growth of US Axial Spondyloarthritis.

The United States Axial Spondyloarthritis market is primarily concerned with diagnosis and treatment of Axial Spondyloarthritis. This market consists of pharmaceutical companies, health insurance providers, major hospitals and diagnostic laboratories.

Key pharmaceutical players include Pfizer, Amgen, AbbVie, Novartis, Bristol Myers Squibb, and Merck & Co. Major Health insurance providers primarily include United Healthcare, Kaiser Foundation, Anthem Inc., Centene Corporation, Humana, and CVS. Major hospitals include Mayo Clinic, Cleveland Clinic, John Hopkins Hospital, UCLA Health, Stanford Health care, and Massachusetts General Hospital. Lastly, key diagnostic laboratories include Unilab, Quest Diagnostics, Empire city laboratories, LabCorp, and Clinical Pathology Laboratories.

This ecosystem is influenced by medical advancements, patient safety regulations, and market competition. The evolving landscape emphasizes research and development for safer and more effective AxSpA drugs, while ensuring compliance with FDA standards to meet the needs of healthcare professionals and patients.

Key trends by Market Segment:

By Types: In 2022, Ankylosing Spondylitis dominated the US Axial Spondyloarthritis market. It is an autoimmune or an inflammatory condition which is known to cause inflammation, pain, and stiffness in spine and joints.

The reason behind its dominance in the US AxSpA is primarily due to its high prevalence. In the United States, the prevalence of Ankylosing Spondylitis is almost 32 people per 10,000 people. Moreover, it is generally caused by the presence of HLA-B27 gene. And a large population also has the presence of this gene.

Almost 7.5% of the Non-Hispanic white people, 4.5% of American-Mexican people, and 1% of Black Non-Hispanic people have the presence of this gene. Such high numbers along with the presence of other autoimmune conditions are the major reasons behind the cause of Ankylosing Spondylitis

By Drug class: In 2022, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) dominated the United States Axial Spondyloarthritis market. These drugs do not have any steroids and are primarily used in the treatment of pain, fever, and inflammation.

The reason why they dominate the US Axial Spondyloarthritis market is that these drugs reduce inflammation and pain which are the major symptoms of AxSpA. Moreover, these drugs are very efficient and effective. And due to their Non-Steroidal property, not only doctors but patients also prefer treating their symptoms with NSAIDs.

Another reason is that they are considered the first line treatment of AxSpA and have a response rate of at most 86%. Furthermore, these are the perfect alternative of opioids which are at times given for pain but have significant side effects.

By Geography: In 2022, the northern region dominated the US Axial Spondyloarthritis market. The reason behind its dominance is primarily due to the presence of many major pharmaceutical companies, top-notch hospitals and diagnostics laboratories.

• This region has the presence of almost 9000 healthcare companies. Some of the well-known pharmaceutical companies situated in this region include Pfizer, Amgen, AbbVie, Bristol Myers Squibb, Novartis and Merck & Co. The presence of all these key players help in accelerating the US Axial Spondyloarthritis market as the new medicines are developed and the clinical efficacy of existing medicines is constantly tried to become better.
• This region also has the presence of many diagnostic laboratories such as Quest Diagnostics, Empire City Laboratories, Bioreference Health LLC, Healthtracx, etc. Due to the presence of these laboratories, the process of diagnosing AxSpA becomes more efficient thereby pumping the US AxSpA market.
• Furthermore, this region also witnesses the presence of famous hospitals. Various hospitals such as Mayo Clinic, Cleveland Clinic, Dana Farber Cancer Institute, Hospitals of University of Pennsylvania, Northwestern Memorial Hospital, Barns-Jewish Hospital, etc. are situated in this area through which many people with Axial Spondyloarthritis take treatment for which ultimately helps in the growth of US AxSpA market.
• Thus, due to the presence of many pharmaceutical company, diagnostic laboratories and hospitals, this region happens to be the dominant region in the US Axial Spondyloarthritis market.

Competitive Landscape:

The United States Axial Spondyloarthritis is equipped with many well-established players which make drugs of all types include NSAIDs, Glucocorticoids, Anti-rheumatic drugs, and others for the treatment of Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis.

Some of the well-known overall drugs makers include Pfizer, Amgen, AbbVie, Bristol Myers Squibb, Merck & Co., and Novartis.

As of the current market scenario, several key players dominate the competitive landscape. Pharmaceutical giants such as AbbVie with their drug adalimumab (brand name Humira) and Pfizer with etanercept (Enbrel) have established a strong foothold. These tumor necrosis factor (TNF) inhibitors have been pivotal in managing symptoms and improving the quality of life for axSpA patients.

Additionally, newer classes of medications have gained traction, intensifying competition. Janus kinase (JAK) inhibitors like tofacitinib (Xeljanz) by Pfizer and secukinumab (Cosentyx) by Novartis, an interleukin-17A inhibitor, have entered the market, offering alternative modes of action. Secukinumab, in particular, has demonstrated efficacy in treating axSpA and has captured a significant market share.

Furthermore, research-driven biotechnology companies are also contributing to the competitive landscape. UCB Pharma's bimekizumab, an interleukin-17A and interleukin-17F inhibitor, has shown promising results in clinical trials for axSpA treatment.

Recent Developments:

• During June 2020, FDA approved Novartis’ Cosentyx for the treatment of active Non-Radiographic Axial Spondyloarthritis.
• During August 2020, an application was sent to FDA by AbbVie for the approval of their drug RINVOQ which is concerned with the treatment of Ankylosing Spondylitis.
• During December 2020, RINVOQ from AbbVie met all the primary and secondary end points in their study for the treatment of non-radiographic Axial Spondyloarthritis.
• During March 2022, IXEKIZUMAB was successful in slowing down the progress of radiographic axial Spondyloarthritis with the treatment of two years.

Future Outlook:

The US Axial Spondyloarthritis market is projected to grow at a CAGR of ~9.5% owing to rise in prevalence of Axial Spondyloarthritis, increase in healthcare expenditure, technological advancements, and many treatment methods.

• As of now, the prevalence of Axial Spondyloarthritis is very high in the US. Its prevalence is 0.9% to 1.4% and this number is only anticipated to grow more. The constant rising prevalence of Axial Spondyloarthritis will only help in further growth of the Axial Spondyloarthritis market.
• The healthcare expenditure also has been rising in the US every year. In 2021, the government made a healthcare expenditure of almost `USD 4 Tn. This expenditure is only expected to further rise which will pump the US Axial Spondyloarthritis market.
• Technology is helping greatly in the diagnosis of Axial Spondyloarthritis. MRI and Ultrasound are the key methods used in the diagnosis of Axial Spondyloarthritis. In the future, more technologies would be coming and would contribute to the growth of US Axial Spondyloarthritis market.
• Right now, there are various treatment options available for AxSpA which primarily include NSAIDs, Anti-Rheumatic drugs, and Glucocorticoids. In the future, the healthcare sector is expected to develop more treatment options. This way, such methods of treating AxSpA will help in the growth of US AxSpA market.